NCT03658031View on ClinicalTrials.gov

Effect of Dapagliflozin on the Progression From Prediabetes to T2DM in Subjects With Myocardial Infarction

PHASE3UnknownINTERVENTIONAL
Enrollment

576

Participants

Timeline

Start Date

March 1, 2019

Primary Completion Date

December 31, 2020

Study Completion Date

January 31, 2021

Conditions
PreDiabetesMyocardial InfarctionT2DM (Type 2 Diabetes Mellitus)CVD
Interventions
DRUG

Dapagliflozin 10mg

Dapagliflozin 10 mg administered each morning before breakfast

Trial Locations (1)

3050

Heart Hospital, Hamad Medical Coorporation, Doha

Sponsors
All Listed Sponsors
lead

Hamad Medical Corporation

INDUSTRY

NCT03658031 - Effect of Dapagliflozin on the Progression From Prediabetes to T2DM in Subjects With Myocardial Infarction | Biotech Hunter | Biotech Hunter